Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects

Recent data from immuno‐oncology clinical studies have shown the exposure–response (E–R) relationship for therapeutic monoclonal antibodies (mAbs) was often confounded by various factors due to the complex interplay of patient characteristics, disease, drug exposure, clearance, and treatment response and presented challenges in characterization and interpretation of E–R analysis. To tackle the challenges, exposure relationships for therapeutic mAbs in immuno‐oncology and oncology are reviewed, and a general framework for an integrative understanding of E–R relationship is proposed. In this framework, baseline factors, drug exposure, and treatment response are envisioned to form an interconnected triangle, driving the E–R relationship and underlying three components that compose the apparent relationship: exposure‐driven E–R, baseline‐driven E–R, and response‐driven E–R. Various strategies in data analysis and study design to decouple those components and mitigate the confounding effect are reviewed for their merits and limitations, and a potential roadmap for selection of these strategies is proposed. Specifically, exposure metrics based on a single‐dose pharmacokinetic model can be used to mitigate response‐driven E–R, while multivariable analysis and/or case control analysis of data obtained from multiple dose levels in a randomized study may be used to account for the baseline‐driven E–R. In this context, the importance of collecting data from multiple dose levels, the role of prognostic factors and predictive factors, the potential utility of clearance at baseline and its change over time, and future directions are discussed.